Loading…

Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy

Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have c...

Full description

Saved in:

Bibliographic Details
Published in:	Annual review of medicine 2008-01, Vol.59 (1), p.95-111
Main Authors:	Moore, Allan F, Florez, Jose C
Format:	Article
Language:	English
Subjects:	Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Endocrinology Genes Genetic Predisposition to Disease - genetics Genetics Humans Hypoglycemic Agents - therapeutic use Pathology Pharmacogenetics
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33
cites	cdi_FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33
container_end_page	111
container_issue	1
container_start_page	95
container_title	Annual review of medicine
container_volume	59
creator	Moore, Allan F Florez, Jose C
description	Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have clarified the etiology of monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies have identified a number of common variants implicated in type 2 diabetes. This year we have witnessed the advent of genome-wide association scanning: As many as nine genetic loci have now been reproducibly associated with type 2 diabetes in five genome-wide scans. Of particular interest are preliminary explorations of the connections between genetic risk and pharmacologic response. An improved understanding of genetic mechanisms should allow us to test whether behavioral or pharmacologic therapies can be tailored and thus the tremendous disease burden inflicted by type 2 diabetes alleviated.
doi_str_mv	10.1146/annurev.med.59.090706.135315
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70207888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1415975801</sourcerecordid><originalsourceid>FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMoun78BSki3lrz0SQNeJFFV2HBgwreQtLOYqTb1iQV-u-NdPHgxdPA8LwzzDwIXRJcEFKKa9N1o4evYgtNwVWBFZZYFIRxRvgeWhBe8pxR8baPFhgLkZeUqCN0HMIHxlgxVh2iIyIVk1zRBXpeQQfR1VkYQw1DdNa1Lk5Z7LM4DZDRrHHGQoSQma7J3HZoXW2i67uQbXqfmtHNRJoR38GbYTpFBxvTBjjb1RP0en_3snzI10-rx-XtOjclkzGnkkkmLLEAHCSjtBK2IYTUlguDqRQEDBWNFHXFsDTcllIIqGtFlamwZewEXc1zB99_jhCi3rp0RNuaDvoxaIkpllVV_QvS9CfOhUrgxR_wox99l47QlFJRSqpIgm5mqPZ9CB42evBua_ykCdY_ivROkU6KNFd6VqRnRSl-vtsx2h_gN7xzwr4BlwWQYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222647291</pqid></control><display><type>article</type><title>Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy</title><source>Annual Reviews Complete A-Z List</source><source>Electronic Back Volume Collection (EBVC)</source><creator>Moore, Allan F ; Florez, Jose C</creator><creatorcontrib>Moore, Allan F ; Florez, Jose C</creatorcontrib><description>Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have clarified the etiology of monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies have identified a number of common variants implicated in type 2 diabetes. This year we have witnessed the advent of genome-wide association scanning: As many as nine genetic loci have now been reproducibly associated with type 2 diabetes in five genome-wide scans. Of particular interest are preliminary explorations of the connections between genetic risk and pharmacologic response. An improved understanding of genetic mechanisms should allow us to test whether behavioral or pharmacologic therapies can be tailored and thus the tremendous disease burden inflicted by type 2 diabetes alleviated.</description><identifier>ISSN: 0066-4219</identifier><identifier>EISSN: 1545-326X</identifier><identifier>DOI: 10.1146/annurev.med.59.090706.135315</identifier><identifier>PMID: 17937592</identifier><language>eng</language><publisher>United States: Annual Reviews, Inc</publisher><subject>Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - genetics ; Endocrinology ; Genes ; Genetic Predisposition to Disease - genetics ; Genetics ; Humans ; Hypoglycemic Agents - therapeutic use ; Pathology ; Pharmacogenetics</subject><ispartof>Annual review of medicine, 2008-01, Vol.59 (1), p.95-111</ispartof><rights>Copyright Annual Reviews, Inc. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33</citedby><cites>FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4182,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17937592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moore, Allan F</creatorcontrib><creatorcontrib>Florez, Jose C</creatorcontrib><title>Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy</title><title>Annual review of medicine</title><addtitle>Annu Rev Med</addtitle><description>Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have clarified the etiology of monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies have identified a number of common variants implicated in type 2 diabetes. This year we have witnessed the advent of genome-wide association scanning: As many as nine genetic loci have now been reproducibly associated with type 2 diabetes in five genome-wide scans. Of particular interest are preliminary explorations of the connections between genetic risk and pharmacologic response. An improved understanding of genetic mechanisms should allow us to test whether behavioral or pharmacologic therapies can be tailored and thus the tremendous disease burden inflicted by type 2 diabetes alleviated.</description><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Endocrinology</subject><subject>Genes</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genetics</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Pathology</subject><subject>Pharmacogenetics</subject><issn>0066-4219</issn><issn>1545-326X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkU1LxDAQhoMoun78BSki3lrz0SQNeJFFV2HBgwreQtLOYqTb1iQV-u-NdPHgxdPA8LwzzDwIXRJcEFKKa9N1o4evYgtNwVWBFZZYFIRxRvgeWhBe8pxR8baPFhgLkZeUqCN0HMIHxlgxVh2iIyIVk1zRBXpeQQfR1VkYQw1DdNa1Lk5Z7LM4DZDRrHHGQoSQma7J3HZoXW2i67uQbXqfmtHNRJoR38GbYTpFBxvTBjjb1RP0en_3snzI10-rx-XtOjclkzGnkkkmLLEAHCSjtBK2IYTUlguDqRQEDBWNFHXFsDTcllIIqGtFlamwZewEXc1zB99_jhCi3rp0RNuaDvoxaIkpllVV_QvS9CfOhUrgxR_wox99l47QlFJRSqpIgm5mqPZ9CB42evBua_ykCdY_ivROkU6KNFd6VqRnRSl-vtsx2h_gN7xzwr4BlwWQYA</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Moore, Allan F</creator><creator>Florez, Jose C</creator><general>Annual Reviews, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy</title><author>Moore, Allan F ; Florez, Jose C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Endocrinology</topic><topic>Genes</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genetics</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Pathology</topic><topic>Pharmacogenetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moore, Allan F</creatorcontrib><creatorcontrib>Florez, Jose C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annual review of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moore, Allan F</au><au>Florez, Jose C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy</atitle><jtitle>Annual review of medicine</jtitle><addtitle>Annu Rev Med</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>59</volume><issue>1</issue><spage>95</spage><epage>111</epage><pages>95-111</pages><issn>0066-4219</issn><eissn>1545-326X</eissn><abstract>Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have clarified the etiology of monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies have identified a number of common variants implicated in type 2 diabetes. This year we have witnessed the advent of genome-wide association scanning: As many as nine genetic loci have now been reproducibly associated with type 2 diabetes in five genome-wide scans. Of particular interest are preliminary explorations of the connections between genetic risk and pharmacologic response. An improved understanding of genetic mechanisms should allow us to test whether behavioral or pharmacologic therapies can be tailored and thus the tremendous disease burden inflicted by type 2 diabetes alleviated.</abstract><cop>United States</cop><pub>Annual Reviews, Inc</pub><pmid>17937592</pmid><doi>10.1146/annurev.med.59.090706.135315</doi><tpages>17</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0066-4219
ispartof	Annual review of medicine, 2008-01, Vol.59 (1), p.95-111
issn	0066-4219 1545-326X
language	eng
recordid	cdi_proquest_miscellaneous_70207888
source	Annual Reviews Complete A-Z List; Electronic Back Volume Collection (EBVC)
subjects	Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Endocrinology Genes Genetic Predisposition to Disease - genetics Genetics Humans Hypoglycemic Agents - therapeutic use Pathology Pharmacogenetics
title	Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A46%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20susceptibility%20to%20type%202%20diabetes%20and%20implications%20for%20antidiabetic%20therapy&rft.jtitle=Annual%20review%20of%20medicine&rft.au=Moore,%20Allan%20F&rft.date=2008-01-01&rft.volume=59&rft.issue=1&rft.spage=95&rft.epage=111&rft.pages=95-111&rft.issn=0066-4219&rft.eissn=1545-326X&rft_id=info:doi/10.1146/annurev.med.59.090706.135315&rft_dat=%3Cproquest_cross%3E1415975801%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a437t-273736b1bee5e732286bd111cb56a02761ea26d76c8307a5b4766ecc929a80b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222647291&rft_id=info:pmid/17937592&rfr_iscdi=true